Scaling Up HCV Therapy Among HIV-Infected Individuals in the Era of Direct-Acting Agents


A 1.5 hour webinar to discuss barriers to care in initiating HCV treatment and update providers on identifying appropriate HCV therapies and therapeutic outcomes. May 21, 2013.

Learning Objectives:

  • Identify ongoing barriers to care that HIV patients face and contribute to HCV treatment delay or deferral.
  • Describe frequency and management of HCV adverse events associated with HCV triple therapy.
  • Describe forthcoming interferon-sparing HCV therapies and their potential impact on the treatment of HCV in HIV infected patients.

Presented by Edward Cachay, MD. Dr. Cachay is an Associate Professor of Clinical Medicine and Medical Director of the HIV Hepatitis Co-Infection Clinic at UC San Diego Medical Center, Owen Clinic. Dr. Cachay has been recognized for excellence in teaching, has published several articles and presented at national conferences on the treatment of HIV and HCV, and serves as co-principal investigator on a five year CDC Prevention with Positives study.

Downloads and Links